Lilly Archives - Journal for Clinical Studies

Regional News

Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly’s Trulicity

Novo Nordisk’s Ozempic, grappling with Eli Lilly’s Trulicity for supremacy of the GLP-1 diabetes market, hit a snag last year when the FDA refused to review a new dos...

30 March 2022 Regional News approval | Lilly

Continue Reading →

Regional News

Lilly and Boehringer’s Jardiance, trailing AZ’s Farxiga in chronic kidney disease, posts efficacy win

After a series of wins in heart failure, Eli Lilly and Boehringer Ingelheim are pumping the breaks on a late-stage Jardiance trial in chronic kidney disease (CKD) tha...

17 March 2022 Regional News Boehringer | chronic

Continue Reading →

Regional News

CMS’ Biogen decision could spell problems for Lilly, Roche Alzheimer’s drugs, half of surveyed neurologists say

Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s c...

2 February 2022 Regional News Alzheimer | Biogen

Continue Reading →

Regional News

Amid new pricing pressure, Lilly cuts cost of generic insulin by another 40%

With drugmakers facing renewed calls to lower the cost of prescription drugs, Eli Lilly has taken preemptive action, dropping the cost of its generic insulin by 40%. ...

29 September 2021 Regional News Eli Lilly | generic insulin

Continue Reading →

Europe

Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache

Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migra...

27 June 2018 Europe 2018 | AHS

Continue Reading →

Europe

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results. AstraZeneca and Eli Lilly’s lanabecesta...

13 June 2018 Europe 3 | Alzheimer

Continue Reading →

Derisking FIH Integrated Strategies

Current Edition

Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly’s Trulicity

Lilly and Boehringer’s Jardiance, trailing AZ’s Farxiga in chronic kidney disease, posts efficacy win

CMS’ Biogen decision could spell problems for Lilly, Roche Alzheimer’s drugs, half of surveyed neurologists say

Amid new pricing pressure, Lilly cuts cost of generic insulin by another 40%

Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

Journal for Clinical Studies